In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hemispherx Biopharma nets $15.1mm privately

Executive Summary

With its second private financing in just over a week, Hemispherx Biopharma (cancer, immunology, and infectious disease therapeutics) has netted $15.1mm through the sale of 11.9mm common shares at $1.34 (a 79% premium) to two institutional investors. The backers also received five-year warrants to buy another 4.2mm shares at $1.31. Rodman & Renshaw Capital was the placement agent.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies